Stryker Corporation
$303.13-1.6%YTD-4.4%1Y-20.7%
Mentions · last 7 days
36
Price updated 8m ago·X counts updated 2d ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $SYK, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Medical - Devices sits in its cycle right now — and what that implies for $SYK.
Medical - Devices
Elective procedure volume recovery and aging-demographic demand are the structural drivers; robotic surgery adoption (ISRG) and GLP-1-driven procedure mix shifts are the near-term dynamics. Hospital capex cycles determine device upgrade timing — CapEx returning after COVID deferral.
What this means for $SYK
Partial — medical device revenue depends on elective procedure volumes and hospital capex; Stryker Corporation functions as a prominent medical technology enterprise, with.
Industry benchmark
8-name peer basket
+3.7%YTD
+44.9%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
36.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
9.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
21.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
3.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
4.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
15.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
63.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$3.69$3.49+5.7%
Q1 2026Apr 30, 2026$2.60$2.98-12.8%
Q4 2025Jan 29, 2026$4.47$4.40+1.6%
Q3 2025Oct 30, 2025$3.19$3.13+1.9%
Next earningsThu, Oct 29·consensus EPS $3.62
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$6.0B+2.6%63.3%15.5%$1.95$415.0M
Q4 FY25$7.2B+11.4%65.2%27.3%$2.21$1.9B
Q3 FY25$6.1B+10.2%63.6%18.7%$2.25$1.4B
Q2 FY25$6.0B+11.1%62.3%22.6%$2.32$928.0M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$27.3B$27.1B – $27.4B$14.98$14.85 – $15.0720
FY27$29.6B$29.0B – $29.9B$16.72$15.49 – $17.0320
FY28$32.0B$31.3B – $32.7B$18.63$17.32 – $20.3120
FY29$34.9B$34.4B – $35.4B$20.83$20.44 – $21.1711
FY30$38.0B$37.4B – $38.4B$23.19$22.75 – $23.5711
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.23%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-6.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-9.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatHigh float · 347.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.775-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KOfficer or director changeMay 208-K — Item 5.02: Officer or director change
AI summary
8-KShareholder voteMay 88-K — Item 5.07: Shareholder vote
SC 13D/AActivist amendmentApr 14SC 13D/A
8-K/APress release / Reg FD (amended)Apr 98-K/A — Item 1.05 · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDMar 238-K — Item 7.01: Press release / Reg FD
8-KPress release / Reg FDMar 128-K — Item 7.01: Press release / Reg FD
+ 11 other (2 10-Qs · 2 earnings 8-Ks · 2 routine 8-Ks · 2 13Gs) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Stryker Launches FDA-Cleared Apple Vision Pro Surgical AppStryker to Acquire ZuriMED to Expand Its Shoulder Care PortfolioStryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical centerStryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offeringCaisse de depot et placement du Quebec Makes New Investment in Stryker Corporation $SYK
More in Medical - Devices
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 2 · last 7 days